CSPC PHARMACEUT.GR. ADR4 (CVGU) — Cash Flow Reinvestment Rate

Latest as of December 2025: 0.74x

CSPC PHARMACEUT.GR. ADR4 (CVGU) has a Cash Flow Reinvestment Rate of 0.74x as of December 2025, reinvesting €4.33 Billion (capex €2.28 Billion plus investments €-2.05 Billion) from operating cash flow of €5.83 Billion. See CSPC PHARMACEUT.GR. ADR4 (CVGU) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.74x
(Capex + Investments) / Operating CF

Total Reinvested

€4.33 Billion
Capex + Investments

Operating Cash Flow

€5.83 Billion
EUR

Capital Expenditures

€2.28 Billion
EUR

CSPC PHARMACEUT.GR. ADR4 Cash Flow Reinvestment Rate (2021–2025)

Historical reinvestment intensity for CSPC PHARMACEUT.GR. ADR4 across 5 annual periods. For the full cash flow conversion analysis, see CVGU operating cash flow.

Annual Cash Flow Reinvestment Rate for CSPC PHARMACEUT.GR. ADR4 (2021–2025)

Year-by-year capital reinvestment analysis for CSPC PHARMACEUT.GR. ADR4. See CSPC PHARMACEUT.GR. ADR4 leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (EUR) Operating CF Capex YoY Change
2025 0.74x €4.33 Billion €5.83 Billion €2.28 Billion ▼ -18.3%
2024 0.91x €4.12 Billion €4.53 Billion €2.68 Billion ▼ -9.1%
2023 1.00x €4.18 Billion €4.18 Billion €1.89 Billion ▲ +15.8%
2022 0.86x €6.59 Billion €7.63 Billion €2.72 Billion ▲ +114.8%
2021 0.40x €1.86 Billion €4.64 Billion €1.76 Billion
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow